Sponsors (4)
The resolution directs attention and resources to prostate cancer research, VA precision oncology, and education — which could improve outcomes and early detection for many men — but it also increases the chance of overdiagnosis/overtreatment and creates budgetary expectations and trade-offs for taxpayers.
Men with prostate cancer — including veterans cared for through the VA — are likely to see improved prevention, detection, and treatment options because the bill highlights increased NIH/NCI research funding and the VA's precision oncology Centers of Excellence.
Patients and health care providers will receive more education and encouragement to discuss prostate cancer screening, which could increase early detection and raise the share of cancers diagnosed at localized stages with very high survival rates.
More emphasis on screening discussions may lead to increased PSA testing, raising the risk of overdiagnosis and overtreatment for men with indolent tumors.
Highlighting large appropriations and new services can raise public expectations and implies trade-offs for the federal budget, potentially increasing costs for taxpayers or crowding out other priorities.
Based on analysis of 2 sections of legislative text.
Records findings on prostate cancer prevalence, risk factors, screening, survival, and research funding and urges education of patients and providers about screening discussions.
Declares congressional findings about prostate cancer — its prevalence, risk factors, the role of screening, survival improvements with early detection, and ongoing research — and stresses the importance of educating patients and health care providers so they discuss screening options. The text cites FY2025 federal research funding levels for NIH and NCI, references Department of Defense and VA prostate cancer research efforts, and highlights continued research and awareness activities. The resolution is informational and aspirational: it documents current research investment and care infrastructure and urges better patient–provider communication about prostate cancer screening rather than creating new programs or changing funding.
Introduced October 6, 2025 by Michael Dean Crapo · Last progress October 6, 2025